AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00651144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
Study NCT00544908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT00544908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00544908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT03294824 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: peripheral blood samples are collected
Study NCT01485120 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BP monitoring using two methods
Description: BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
Study NCT02493946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT02493946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01831037 — intervention group
Intervention type: OTHER
Intervention: Regression of fibrosis
Description: Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
Study NCT01831037 — intervention group
Intervention type: OTHER
Intervention: Specific risk factors related to hepatocellular carcinoma
Description: Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
Study NCT02593123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO, by mouth, orally or IV, intravenous medication administration.
Study NCT02593123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Given PO, by mouth, orally or IV, intravenous medication administration.
Study NCT02593123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF.
Study NCT02593123 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Study NCT03940690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF injections of bevacizumab
Description: 5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
Study NCT03940690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: 3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
Study NCT02638883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid SRW cochlear implant
Description: Subjects will be implanted with the Hybrid SRW
Study NCT02519946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-Line Diet and Exercise Intervention
Description: Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
Study NCT00431613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
Study NCT00431613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
Study NCT00431613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
Study NCT00431613 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32
Study NCT00431613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV on day 1 for 3 cycles
Study NCT00356005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin plus artesunate
Study NCT00356005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Study NCT01193010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgical Planning
Description: Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
Study NCT01193010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distal radius osteotomy
Description: In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
Study NCT00843427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIAT
Description: Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
Study NCT00905047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: XELODA
Description: XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days
Study NCT00905047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TEGAFUR URACIL - FOLINIC ACID
Description: Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days.
Study NCT05396508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interfacial injection
Description: 10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
Study NCT05396508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
Study NCT00895895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
Study NCT00895895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 1.5 mg
Description: Capsules SAM-531 1.5 mg, once a day during 52 weeks.
Study NCT00895895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 3.0 mg
Description: Capsules SAM-531 3.0 mg, once a day during 52 weeks.
Study NCT00895895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 5.0 mg
Description: Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
Study NCT00895895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
Study NCT00560144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 3mg/kg iv weekly
Study NCT00560144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 9mg/kg iv weekly
Study NCT00560144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
Study NCT03690427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional hookah smoking
Description: Charcoal-heated hookah smoking
Study NCT03690427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping
Description: Electronic hookah bowl inhalation
Study NCT00673907 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wood smoke particles
Description: Subjects are exposed at rest to the exposures for 3 h in our climate chamber
Study NCT00673907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wood smoke particles
Description: Subjects are exposed at rest to the exposures for 3 h in our climate chamber
Study NCT03798873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeelWell™ Compression garment
Description: Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back.
Study NCT03798873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Mobility
Description: Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
Study NCT03798873 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increase Mobility
Description: Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
Study NCT04787237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VST and immediate implants
Description: One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
Study NCT04787237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buser technique and early implants placement
Description: In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
Study NCT04264715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 405nm light
Description: In this room, surgeries will be performed under ambient light including the wavelength 405nm
Study NCT00098527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00098527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02931305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimedium Prenylflavonoids Extract
Description: Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
Study NCT02931305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
Study NCT01465945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Defect Unsutured
Description: The defect is not sutured after the rectal tumor is removed by TEM.
Study NCT01465945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Defect Sutured
Description: Defect is sutured after the rectal tumor has been removed by TEM.
Study NCT01224470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedetomidine intravenous injection (1 ㎍/kg )
Study NCT01224470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedetomidine intravenous injection (1 ㎍/kg )
Study NCT03117764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfet Dynamometer
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT03117764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microfet Dynamometer
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT03117764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 minute sit to stand test
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT03117764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 minute sit to stand test
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT03117764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT03117764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist.
Study NCT00281320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
Study NCT00798434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo administered orally in the morning or evening.
Study NCT00544908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00544908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00974038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: 1) cognitive-behavioral therapy or 2) supportive psychotherapy
Study NCT03603288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone 150 mg film-coated tablets
Description: 900 mg idebenone/day
Study NCT01592604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive bandage
Description: Compressive below knee bandage for 4 weeks in group A
Study NCT01592604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below knee walking cast
Description: Below knee walking cast for 4 weeks
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GFT505 120mg - old formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 120mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 180mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 240mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 300mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
Study NCT01474161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
Study NCT00798434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine fumarate
Description: Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
Study NCT04049305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted nipple sparing mastectomy (R-NSM)
Description: R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
Study NCT04921579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En masse retraction
Description: Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.